CCT8L1 Inhibitors
CCT8L1 inhibitors represent a class of chemical agents specifically designed to suppress the activity of the CCT8L1 protein, which is implicated in essential cellular processes. These inhibitors function through a variety of mechanisms, each targeting the CCT8L1 protein's ability to contribute to the stability and function of the cytoskeletal framework and its role in proper cell division and signaling. By disrupting the CCT8L1 protein's interaction with its co-factors and substrates, these compounds effectively reduce its functional activity within the cell. The inhibition can be achieved through direct binding to the CCT8L1 protein, thereby altering its conformation and preventing its normal operation. Alternatively, they might interfere with the upstream regulation of CCT8L1, hindering its expression or its post-translational modifications that are crucial for its activity. The precise inhibition mechanisms vary among different CCT8L1 inhibitors, but they all converge on the common goal of dampening the functional role of CCT8L1 in the cell.
The specificity of CCT8L1 inhibitors ensures that their impact is restricted to the intended targets, minimizing off-target effects that are a common pitfall in the development of such chemical compounds. By focusing on the unique aspects of CCT8L1's structure and function, these inhibitors can achieve a high degree of efficacy. They play a crucial role in elucidating the biological pathways in which CCT8L1 is involved, providing valuable insights into the protein's role in cellular homeostasis. The inhibitors' actions elucidate the consequences of CCT8L1 inhibition on cellular processes, helping to map the complex network of interactions in which CCT8L1 participates. With their precise targeting and the resulting detailed understanding of CCT8L1's functions, these inhibitors are powerful tools in cellular and molecular biology research, contributing to the foundational knowledge required to comprehend the intricate web of cellular signaling and structural dynamics.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). CCT8L1, being a chaperonin, may rely on proper protein folding and assembly pathways mediated by PI3K signaling. Inhibition of PI3K by Wortmannin could disrupt this process, indirectly affecting CCT8L1 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits the mammalian target of rapamycin (mTOR), a key kinase that regulates protein synthesis and cell growth. Since CCT8L1 is involved in protein folding, inhibition of mTOR by Rapamycin could decrease the demand for chaperonin function, thus indirectly inhibiting CCT8L1. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. It alters chromatin structure and affects gene expression. CCT8L1 could be indirectly inhibited if Trichostatin A represses the expression of genes encoding proteins that require CCT8L1 for proper folding. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K. By blocking PI3K signaling, it could disrupt cellular processes that depend on proper protein folding mediated by CCT8L1, leading to an indirect inhibition of its function. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules and inhibits their disassembly. CCT8L1, which may interact with cytoskeletal elements during protein folding, could be indirectly inhibited if microtubule dynamics are altered by Paclitaxel. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A is an immunosuppressant that inhibits calcineurin. As CCT8L1 may have a role in pathways influenced by calcium signaling, the inhibition of calcineurin could indirectly affect CCT8L1’s activity. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin is known to interfere with multiple signaling pathways, including the inhibition of NF-κB. Since NF-κB signaling can regulate the expression of molecular chaperones, CCT8L1 function might be indirectly inhibited by curcumin. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin binds to Hsp90 and inhibits its chaperone activity. Since Hsp90 is involved in the folding of many proteins, inhibiting Hsp90 could reduce the overall protein folding demand, indirectly affecting CCT8L1 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pump inhibitor, leading to increased cytosolic calcium levels. This disturbance in calcium homeostasis could indirectly affect CCT8L1 function as it may be involved in calcium-dependent signaling pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By preventing the degradation of misfolded proteins, it can increase the stress on protein folding machinery, potentially overloading CCT8L1 activity and indirectly inhibiting its function. | ||||||